Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD) (FIND-CKD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00994318|
Recruitment Status : Completed
First Posted : October 14, 2009
Results First Posted : May 7, 2014
Last Update Posted : May 20, 2014
|Condition or disease||Intervention/treatment||Phase|
|Iron Deficiency Anaemia Chronic Kidney Disease||Drug: FCM (Ferric carboxymaltose) high ferritin target Drug: FCM (Ferric carboxymaltose) low ferritin target Drug: Oral Iron (Ferrous sulphate)||Phase 3|
After an initial screening period of up to 4 weeks, eligible subjects were randomised (1:1:2) to 1 of the following 3 treatment arms for a period of 52 weeks.
- FCM regimen (maximum single intravenous doses of 1,000 mg of iron) targeting a ferritin level of 400-600 mcg/L.
- FCM regimen (maximum single intravenous doses of 200 mg of iron) targeting a ferritin level of 100-200 mcg/L.
- Daily oral iron with 200 mg iron/day (100 mg twice daily)
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||626 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open-label, Multicentre, Randomised, 3-arm Study to Investigate the Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (Ferinject High and Low Dosage Regimens) Versus Oral Iron for the Treatment of Iron Deficiency Anaemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease|
|Study Start Date :||December 2009|
|Actual Primary Completion Date :||February 2013|
|Actual Study Completion Date :||February 2014|
Experimental: FCM (high ferritin target)
Ferric carboxymaltose (FCM) (Ferinject / Injectafer) targeting ferritin level of 400 - 600 mcg/L
Drug: FCM (Ferric carboxymaltose) high ferritin target
Experimental: FCM (low ferritin target)
Ferric carboxymaltose (FCM) (Ferinject / Injectafer) targeting ferritin level of 100 - 200 mcg/L
Drug: FCM (Ferric carboxymaltose) low ferritin target
Active Comparator: Oral Iron
Ferrous sulphate 100 mg iron twice daily, continuous
Drug: Oral Iron (Ferrous sulphate)
Other Name: Ferrous sulphate
- Kaplan-Meier Survival Analysis for Time to Other Anemia Therapy or Hb Trigger [ Time Frame: Up to 1 year after baseline ]
Endpoint reported number of participants with/without events and was reached:
- First time of initiation of additional or alternative anaemia management,
First time the subject reached the Hb trigger.
3 primary comparisons using a hierarchical step-down procedure on the log-rank test to preserve an alpha level of 0.05, performed in the following order:
- FCM (high ferritin target) compared with oral iron.
- FCM (high ferritin target) compared with FCM (low ferritin target).
- FCM (low ferritin target) compared with oral iron.
Sensitivity analyses of the primary endpoint were performed using the following alternative definitions of time to initiation of additional or alternative anaemia management:
- Without taking into account the Hb trigger.
- Taking into account the Hb trigger based on local laboratory data, instead of central laboratory data.
- Taking into account the Hb trigger based on subjects with a complete set of Hb values from the central laboratory.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00994318
|Principal Investigator:||Iain Macdougall||King's College Hospital NHS Trust|